Neurol. praxi. 2019;20(5):368-372 | DOI: 10.36290/neu.2019.059

The neuromyelitis optica spectrum disorders

doc. MUDr. Jarmila Szilasiová, PhD.
Neurologická klinika UPJŠ LF a Univerzitná nemocnica L. Pasteura, Košice

The neuromyelitis optica spectrum disorders (NMOSD) includes neuromyelitis optica – NMO (characterized typically by optical neuritis and myelitis) and other particularly limited forms that include involvement of other parts of the CNS (brainstem, diencephalon, hypothalamus). NMOSD prevalence is low, but severe and rapid progressive disability in patients has led to extensive research in the field of diagnostics as well as therapeutic approaches in recent years. The discovery of specific serum immunoglobulin G antibodies selectively targeted to aquaporin 4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) have led to an understanding of different disease characteristics. In 2015 the currently valid diagnostic criteria for NMOSD were developed. The treatment is targeted to managing relapses and consequently preventing further events by immunosuppressants and monoclonal antibodies.

Keywords: spectrum neuromyelitis optica disorders, AQP4-IgG, MOG-IgG, eculizumab, satralizumab, inebilizumab

Received: August 15, 2019; Accepted: August 19, 2019; Prepublished online: August 19, 2019; Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Szilasiová J. The neuromyelitis optica spectrum disorders. Neurol. praxi. 2019;20(5):368-372. doi: 10.36290/neu.2019.059.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, Glogowska M, Case D, Antel JP, Owens GP, Gilden D, Nessler S, Stadelmann C, Hemmer B. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009; 66(5): 617-629. Go to original source... Go to PubMed...
    2. Collongues N, Ayme-Dietrich E, Monassier L, de Seze J. Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: current management and future options. Drugs 2019; 79(2): 125-142. Go to original source... Go to PubMed...
    3. Devic E. Myelite subaigue compliquee de nevrite optique. Bull. Med. 1894; 8: 1033.
    4. Etemadifar M, Nasr Z, Khalili B, de Seze J. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Mult. Scler. Int. 2015: 174720. Go to original source... Go to PubMed...
    5. Fragoso YD, Adoni T, Bichuetti DB, Brooks JB, Ferreira ML, Oliveira EM, Oliveira CL, Ribeiro SB, Silva AE, Siquineli F. Neuromyelitis optica and pregnancy. J Neurol. 2013; 260(10): 2614-2619. Go to original source... Go to PubMed...
    6. Gault F. De la neuromyélite optique aiguë. Ph.D. Thesis, Alexandre Rey, imprimeur de la faculté de médecine, Faculté de Medicine et de Pharmacie de Lyon, Lyon, France: 1894.
    7. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, Ringelstein M, Trebst C, Winkelmann A, Schwart A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechnes K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B, in cooperation with the Neuromyelitis Optica Study group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J. Neuroinflamm. 2016; 13: 280. Go to original source... Go to PubMed...
    8. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kűmpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm. 2018; 15(1): 134. Go to original source... Go to PubMed...
    9. Kim Y, Kim G, Kong BS, Lee JE, Oh YM, Hyun JW, Kim SH, Joung A, Kim BJ, Choi K, Kim HJ. Large-scale in-house Cell-Based Assay for evaluating the serostatus in patients with neuromyelitis optica spectrum disorder based on new diagnostic criteria. J Clin Neurol. 2017; 13(2): 175-180. Go to original source... Go to PubMed...
    10. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015; 84(11): 1165-73. Go to original source... Go to PubMed...
    11. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kumpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C. NEMOS (Neuromyelitis optica study group). Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018; 5(6): e504. Go to original source... Go to PubMed...
    12. López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 2018; 75(11): 1355. Go to original source... Go to PubMed...
    13. Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. J. Neurol. Neurosurg. Psychiatry. 2018; 89: 55-556. Go to original source... Go to PubMed...
    14. Nytrová P, Horáková D. Neuromyelitis optica. Cesk Slov Neurol N. 2015; 78/111(2): 130-137. Go to original source...
    15. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012; 11: 535-544. Go to original source... Go to PubMed...
    16. Paul F, Murphy O, Pardo S, Levy M. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin. Investig. Drugs 2018; 27: 265-271. Go to original source... Go to PubMed...
    17. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM. Eculizumab in Aquaporin-4-positive Neuromyelitis optica spectrum disorder. N Engl J Med. 2019; May 3. doi: 10.1056/NEJMoa1900866. Go to original source... Go to PubMed...
    18. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006; 63(3): 390-396. Go to original source... Go to PubMed...
    19. Pivotal study results of Inebilizumab in patients with Neuromyelitis Optica Spectrum Disorder presented at the American Academy of Neurology Annual Meeting. Viela Bio. Gaithersburg, MD, AAN, May 7, 2019.
    20. Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing mog antibody-associated demyelination. J. Neurol. Neurosurg. Psychiatry. 2018; 89: 127-137. Go to original source... Go to PubMed...
    21. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Lino AM, Misu T, Leite MI, Aoki M, Fujihara K. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82(6): 474-481. Go to original source... Go to PubMed...
    22. Sherman E, Han MH. Acute and chronic management of Neuromyelitis optica spectrum disorder. Curr Treat Options Neurol. 2015; 17(11): 48. Go to original source... Go to PubMed...
    23. Shosha E, Pittock SJ, Flanagan E, Weinshenker BG. Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. Mult Scler. 2017; 23(14): 1808-1817. Go to original source... Go to PubMed...
    24. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kumpfel T; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group. J. Neurol. 2014; 261: 1-16. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group. J. Neurol. 2014; 261: 1-16. Go to original source... Go to PubMed...
    25. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carrol W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2): 177-189. Go to original source... Go to PubMed...
    26. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6(9): 805. Go to original source... Go to PubMed...
    27. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66(10): 1485-1489. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.